For anyone who has been through a kidney transplant, protecting that precious new organ becomes part of everyday life. Alongside the medicines that help the body accept the kidney, patients often have to stay alert to infections that healthier immune systems would shrug off without a second thought. A fresh piece of UK research into a promising CMV vaccine offers a hopeful glimpse of how one of the most common threats to transplant recipients might one day be kept at bay more effectively.
What did the UCL team discover about the CMV vaccine?
New findings, published in March 2026 in the journal npj Vaccines and funded by Kidney Research UK, have shed fresh light on how the immune system responds to a promising cytomegalovirus (CMV) vaccine. The work was led by Professor Matthew Reeves and colleagues at University College London, who examined blood samples from people who had received the gB/MF59 vaccine, one of the most advanced CMV jabs in development.
The team focused on a specific antibody, known as AD-6, that the vaccine teaches the body to produce. They mapped exactly where this antibody attaches to the virus, homing in on a protein called glycoprotein B which sits on the surface of CMV and helps it invade cells. Their results suggest AD-6 does something unusual and important: it blocks CMV from spreading between cells inside the body, not just from latching onto fresh ones.
Using a mix of computer modelling and laboratory techniques, the researchers also discovered that AD-6 recognises parts of the virus that shift shape during infection. That raises the possibility of interrupting CMV at a critical moment in its life cycle, and hints that similar strategies might work against other herpes-family viruses too.
Read the full research summary from Kidney Research UK.
Why CMV matters for kidney transplant recipients
CMV is part of the same viral family as the viruses that cause cold sores, chickenpox and glandular fever, and more than half of the world’s population carries it for life. For most people it causes little or no trouble. For kidney transplant recipients, however, the picture is very different. The immunosuppressant medicines that guard a new kidney against rejection also soften the body’s defences, leaving patients more exposed to CMV reactivation and new infection. In the most serious cases this can make people genuinely unwell and raise the risk of complications for the transplanted kidney.
A better targeted CMV vaccine, designed with transplant patients in mind, could take one more worry off the shoulders of people already navigating plenty.
Where this research stands on the path to clinical use
It is worth being clear about what this study is and is not. This is laboratory and clinical-trial data, not a vaccine you can request today from your GP or renal team. The findings will help to shape the next generation of CMV vaccine design, but further trials are needed before any new product could be offered routinely to transplant recipients. What it does tell us is that scientists are zeroing in on the right targets, and that the research community has not forgotten who the most vulnerable patients are.
A Manchester community keeping an eye on the science
At MRIKPA we are a community of kidney patients, carers and family members based around the Manchester Royal Infirmary. Many of us have lived through transplant ourselves and understand how much mental weight infections like CMV can carry in the months and years afterwards. We make it our business to follow research like this and share it with our members in plain language.
Research like this is exactly the kind of news that gives our community a genuine lift. It reminds us that teams across the UK are quietly working on the things that really affect daily life after a transplant, and that kidney patients have not been forgotten.
– Guy Hill, Chair of MRIKPA
If you live with kidney disease, or you are supporting someone who does, we would love to hear from you. You can get in touch at support@mrikpa.org.uk, or give us a call on 07745 242 684 to speak with someone who understands kidney life from the inside. We are not a helpline, just fellow patients who are happy to share experiences, a cup of tea and a friendly ear.
Source: Kidney Research UK, March 2026 – read the original article
This article is provided for general information and awareness purposes only and was believed to be accurate at the time of publishing. It is not intended as medical advice — please always consult your doctor or renal team for guidance on your individual circumstances. Images used are for illustration purposes only and may not be medically or editorially accurate. While we take every care, errors can occur. If you spot an inaccuracy, please let us know at support@mrikpa.org.uk.
